These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 11177336)

  • 1. Thrombus formation on atherosclerotic plaques: pathogenesis and clinical consequences.
    Rauch U; Osende JI; Fuster V; Badimon JJ; Fayad Z; Chesebro JH
    Ann Intern Med; 2001 Feb; 134(3):224-38. PubMed ID: 11177336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The evolving role of platelet glycoprotein IIb/IIIa inhibitors in the management of acute coronary syndromes.
    Stringer KA
    Ann Pharmacother; 1999 Jun; 33(6):712-22. PubMed ID: 10410186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycoprotein Ibalpha inhibition and ADP receptor antagonists, but not aspirin, reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaques.
    Penz SM; Reininger AJ; Toth O; Deckmyn H; Brandl R; Siess W
    Thromb Haemost; 2007 Mar; 97(3):435-43. PubMed ID: 17334511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiplatelet intervention in acute coronary syndrome.
    Arora RR; Rai F
    Am J Ther; 2009; 16(5):e29-40. PubMed ID: 19092648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of platelet glycoprotein IIb/IIIa antagonists in percutaneous coronary revascularization procedures.
    Dangas G; Fuster V
    Rev Port Cardiol; 1999 Feb; 18 Suppl 1():I49-53. PubMed ID: 10191675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of microsurgical thrombosis by the platelet glycoprotein IIb/IIIa antagonist SR121566A.
    Ching S; Thoma A; Monkman S; Kelton JG
    Plast Reconstr Surg; 2003 Jul; 112(1):177-85. PubMed ID: 12832891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atherothrombosis: epidemiology, pathophysiology, and prevention.
    Munger MA; Hawkins DW
    J Am Pharm Assoc (2003); 2004; 44(2 Suppl 1):S5-12; quiz S12-3. PubMed ID: 15095931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular wall hypoxia promotes arterial thrombus formation via augmentation of vascular thrombogenicity.
    Matsuura Y; Yamashita A; Iwakiri T; Sugita C; Okuyama N; Kitamura K; Asada Y
    Thromb Haemost; 2015 Jul; 114(1):158-72. PubMed ID: 25833755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions.
    Badimon JJ; Lettino M; Toschi V; Fuster V; Berrozpe M; Chesebro JH; Badimon L
    Circulation; 1999 Apr; 99(14):1780-7. PubMed ID: 10199872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New targets for antithrombotic drugs.
    Thiagarajan P
    Am J Cardiovasc Drugs; 2002; 2(4):227-35. PubMed ID: 14727968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plaque rupture, thrombosis, and therapeutic implications.
    Fuster V; Badimon J; Chesebro JH; Fallon JT
    Haemostasis; 1996 Oct; 26 Suppl 4():269-84. PubMed ID: 8979133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The clinical use of the GPIIb/IIIa inhibitors eptifibatide and tirofiban in the treatment of acute coronary syndromes of the "non-ST elevation" type].
    Galli M; Maggioni AP; Vassanelli C; Tavazzi L
    Ital Heart J Suppl; 2000 Feb; 1(2):202-11. PubMed ID: 10731377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined effects of a factor Xa inhibitor YM466 and a GPIIb/IIIa antagonist YM128 on thrombosis and neointima formation in mice.
    Iwatsuki Y; Kawasaki T; Hayashi K; Moritani Y; Nii T; Miyata K
    Thromb Haemost; 2004 Dec; 92(6):1221-8. PubMed ID: 15583727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atherothrombosis and Thromboembolism: Position Paper from the Second Maastricht Consensus Conference on Thrombosis.
    Spronk HMH; Padro T; Siland JE; Prochaska JH; Winters J; van der Wal AC; Posthuma JJ; Lowe G; d'Alessandro E; Wenzel P; Coenen DM; Reitsma PH; Ruf W; van Gorp RH; Koenen RR; Vajen T; Alshaikh NA; Wolberg AS; Macrae FL; Asquith N; Heemskerk J; Heinzmann A; Moorlag M; Mackman N; van der Meijden P; Meijers JCM; Heestermans M; Renné T; Dólleman S; Chayouâ W; Ariëns RAS; Baaten CC; Nagy M; Kuliopulos A; Posma JJ; Harrison P; Vries MJ; Crijns HJGM; Dudink EAMP; Buller HR; Henskens YMC; Själander A; Zwaveling S; Erküner O; Eikelboom JW; Gulpen A; Peeters FECM; Douxfils J; Olie RH; Baglin T; Leader A; Schotten U; Scaf B; van Beusekom HMM; Mosnier LO; van der Vorm L; Declerck P; Visser M; Dippel DWJ; Strijbis VJ; Pertiwi K; Ten Cate-Hoek AJ; Ten Cate H
    Thromb Haemost; 2018 Feb; 118(2):229-250. PubMed ID: 29378352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Wall passivation for unstable angina.
    Lettino M; Dailey-Sterling F; Badimon L; Chesebro JH; Badimon JJ
    Semin Interv Cardiol; 1996 Mar; 1(1):60-6. PubMed ID: 9552495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathophysiology of atherothrombosis: Mechanisms of thrombus formation on disrupted atherosclerotic plaques.
    Asada Y; Yamashita A; Sato Y; Hatakeyama K
    Pathol Int; 2020 Jun; 70(6):309-322. PubMed ID: 32166823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequency and efficacy of glycoprotein IIb/IIIa therapy for treatment of threatened or acute vessel closure in 1332 patients undergoing percutaneous transluminal coronary angioplasty.
    Haase KK; Mahrholdt H; Schröder S; Baumbach A; Oberhoff M; Herdeg C; Karsch KR
    Am Heart J; 1999 Feb; 137(2):234-40. PubMed ID: 9924156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel, or both?
    Silva MA; Donovan JL; Gandhi PJ; Volturo GA
    Vasc Health Risk Manag; 2006; 2(1):39-48. PubMed ID: 17319468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The emerging role of platelet glycoprotein IIb/IIIa inhibitors in managing high-risk patients with non-ST segment elevation acute coronary syndromes.
    Bolognese L
    Curr Med Res Opin; 2007 Jun; 23(6):1217-26. PubMed ID: 17559721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New antithrombotic drugs on the horizon.
    Ruef J; Katus HA
    Expert Opin Investig Drugs; 2003 May; 12(5):781-97. PubMed ID: 12720490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.